FDA and CMS work to resolve state federal conflict over health AI regulation
Federal health officials are coordinating behind the scenes to manage jurisdictional conflicts between states and the government regarding artificial intelligence in clinical settings.
Overlapping authority creates regulatory tension
States currently regulate medical practice and issue licenses to clinicians. If AI performs tasks like writing prescriptions without human supervision, those products fall under FDA jurisdiction. This overlap between state licensing and federal device regulation has created a potential logjam for developers.
Administration seeks to ease burdens
The Trump administration has introduced new payment methods to support the technology. Officials also aim to reduce regulatory burdens on companies building health AI tools. These efforts come as more states look to test artificial intelligence in their clinical environments.
Adoption faces structural hurdles
Health officials hope these changes will boost adoption of the technology across the sector. The conflict remains unresolved despite behind-the-scenes movements by federal agencies. Developers must navigate both state licenses and federal approvals to launch clinical AI products.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.